Nimacimab is under clinical development by Skye Bioscience and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nimacimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nimacimab overview
Nimacimab (RYI-018) is under development for the treatment of liver fibrosis including non-alcoholic steatohepatitis (NASH), chronic kidney disease, non-alcoholic fatty liver disease and obesity. It is administered through intravenous and subcutaneous routes. The drug candidate is a negative allosteric modulating monoclonal antibody. It acts by targeting cannabinoid receptor-1 (CB-1). RYI-018 is developed by using RuiYi’s iCAPS platfrom (intermembranous conformation antigen presenting system). The drug candidate is a new molecular entity (NME).
Nimacimab (RYI-018) was under development for the treatment of diabetic nephropathy (diabetic kidney disease), diabetic gastroparesis, focal segmental glomerulosclerosis (FSGS), diabetic nephropathy (diabetic kidney disease) and immunoglobulin A (IgA) nephropathy.
Skye Bioscience overview
Skye Bioscience, a subsidiary of Emerald Health Sciences Inc, is a life-science and biopharmaceutical and healthcare company. The company product portfolio includes THCVHS, CBDVHS, and Cannabinoid Cocktail products. Its products are in preclinical and research stages. Skye Bioscience CBDVHS product carter’s treatment for eye diseases, such as dry eye syndrome, uveitis, macular degeneration, and diabetic retinopathy. Its lead program, SBI-100, is involved in treating glaucoma disease. The company also develops novel and proprietary classes of product candidates that improve therapeutic options through enhanced chemical engineering and allow drug candidates to predictable bioavailability and pharmacokinetics. It has operations across the US. Skye Bioscience is headquartered in San Diego, California, the US.
For a complete picture of Nimacimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
